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Background : Cell replacement therapy (CRT) for Huntington disease (HD) requires a source of striatal (STR)
progenitors capable of restoring the function lost due to STR degeneration. Authentic STR progenitors can be
collected from the fetal putative striatum, or whole ganglionic eminence (WGE), but these tissues remain
impractical for widespread clinical application, and alternative donor sources are required. Here we begin
exploring the possibility that induced pluripotent stem cells (iPSC) derived from WGE may retain an epige-
netic memory of their tissue of origin, which could enhance their ability to differentiate into STR cells.
Results:We generate four iPSC lines from humanWGE (hWGE) and establish that they have a capacity similar
to human embryonic stem cells with regard to their ability to differentiate toward an STR phenotype, as mea-
sured by expression and demethylation of key STR genes, while maintaining an overall different methylome.
Finally, we demonstrate that these STR-differentiated hWGE iPSCs share characteristics with hWGE (i.e.,
authentic STR tissues) both in vitro and following transplantation into an HD model. Overall, iPSCs derived
from humanWGE show promise as a donor source for CRT for HD.







striatal differentiationRepair Group, School of Bio-
f.ac.uk (A.E. Rosser).
Therapy. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)Introduction
Huntington disease (HD) is a neurodegenerative condition associ-
ated with motor, cognitive and psychiatric symptoms [1]. One of the
earliest and most prominent neuropathological features is the grad-
ual and progressive loss of striatal (STR) medium spiny neurons
(MSNs), with further atrophy occurring in other brain regions as the
disease progresses [2,3]. There is currently no cure, and HD patients
typically die within 1530 years of disease onset. Cell replacement
therapy (CRT) is a potential medical intervention for HD, aiming to
restore function by replenishing the degenerating MSN population.
Intra-STR allografts of MSN progenitors derived from primary fetal
whole ganglionic eminence (WGE), the primordial striatum, havebeen shown to express DARPP-32 (PPP1R1B), the principal marker of
MSNs, and bring about motor and cognitive functional recovery in
HD rat models. Similarly, expression of DARPP-32 donor-derived cells,
along with functional improvements, has been observed in xeno-
grafts of human WGE (hWGE) in the HD rat striatum [4]. CRT clinical
trials have provided evidence of safety and feasibility of intra-STR
transplantation of primary hWGE in HD patients. Furthermore, there
is some evidence of long-term graft survival and functional benefits
to transplant recipients [5,6]. As such, primary hWGE tissues are cur-
rently considered the gold standard donor source for CRT in HD, but
they also present a plethora of logistical, quality control and ethical
challenges for clinical translation. Hence, there is interest in identify-
ing renewable MSN progenitor sources for clinical application [7].
Human pluripotent stem cells (hPSCs), principally human embry-
onic stem cells (hESCs) and human induced PSCs (iPSCs), are an
appropriate alternative donor source, as they are renewable, accessi-
ble for quality control and theoretically capable of differentiating
toward an STR fate [4]. There is evidence that iPSCs inherit some
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derived, which results in some retained phenotypic features [8,9].
Specific examples include iPSCs derived from insulin-producing b
cells [10] and hematopoietic [11], cardiac [12], ocular [13] and neural
[14] tissues. Critically, iPSCs derived from forebrain progenitors have
been demonstrated to possess an enriched gene expression profile
typical of their region of origin, which is reported to enhance their
survival following transplantation into the rodent forebrain [15].
Based on the notion that iPSCs can retain an epigenetic profile char-
acteristic of their tissue of origin, we asked whether iPSCs derived
from hWGE would be epigenetically primed to differentiate toward
STR fates. Specifically, we sought to broadly establish how hWGE-
derived iPSCs compared with hWGE in terms of key gene expression
markers, epigenetic signatures and engraftment potential.
Methods
Ethics and approval
Human fetal tissue was obtained via SWIFT-RTB with full ethical
approval and under the UK Human Tissue Authority research license
held by Cardiff University (No. 12422). All procedures with animals
were performed in full compliance with the UK Animals Act 1986
(Scientific Procedures) and approved by local ethical review.
Human WGE iPSC generation, culture and validation
Human WGE iPSC generation is described in Supplementary
Materials and Methods. In brief, hWGE was dissected and dissociated
as previously described [16]. Human WGE iPSCs were generated by
transfecting hWGE with piggyBac transposons and transposase
(Sanger Institute). Pluripotent-like colonies were identified micro-
scopically, manually picked and then cultured separately as clones,
following which integrated transposons were removed [17]. Human
PSCs were maintained on irradiated mouse embryonic fibroblasts in
ReproStem medium (ReproCell) supplemented with basic fibroblast
growth factor (bFGF) (25 mg/500 mL). For spontaneous differentia-
tion, bFGF was removed from culture for 1421 days. For teratoma
formation, hWGE iPSCs (1 £ 106) were injected subcutaneously into




Three types of media were used for differentiation: (i) KnockOut
(K/O) medium, as DMEMF/12, KnockOut Serum Replacement (1:100),
L-glutamine (200 mM), non-essential amino acid (1:100) and penicil-
lin-streptomycin (1:100) (all Gibco), and b-mercaptoethanol (50
mM; Sigma);
(ii) N2B27 medium, as Advanced DMEM/F12: Neurobasal (1:1), N2
(1:150) and B27 (+RA, 1:150) (all Gibco);
and (iii) N2B27-RA medium, as N2B27 without RA.
Protocol
On day 2, hWGE iPSCs were passaged into small clumps and
transferred to ReproStem without bFGF to form embryoid bodies
(EBs). On day 0, EBs were transferred to K/O medium with SB431542
(10 mM), dorsomorphin (200 mM) (Tocris) and Noggin (500 mg/mL;
R&D). On day 5, EBs were transferred to N2B27 medium with SHH
(100 ng/mL) and DKK1 (100 ng/mL) (both R&D). On day 10, EBs were
plated on Matrigel (Corning) coated plates in N2B27 medium +SHH
+DKK1. On day 16, cells were dissociated with Accutase (Sigma),
plated on poly-l-lysine/laminin-coated six-well plates (1 £ 106 cells/
well) and cultured in N2B27-RA medium +SHH+DKK1. On day 20,
Activin A (25 ng/mL; R&D) was added to N2B27-RA. On day 22, cellswere passaged as single cells onto poly-l-lysine/laminin-coated six-
well plates (1 £ 106 cells/well). From day 30 onward, medium was
changed to N2B27 with brain-derived neurotrophic factor (100 ng/
mL) and glial cell-derived neurotrophic factor (10 ng/mL) (both
PeproTech) as well as ascorbic acid (200 mg/mL) and valproic acid
(10 mM) (both Sigma).
Immunochemistry
Protocol and primary antibodies are described in Supplementary
Materials and Methods. Analysis was performed using a Leica DMRBE
microscope with Axiocam software.
DNA methylation analysis
DNA was extracted using a QIAamp DNA mini kit (Qiagen). DNA
was bisulfite-converted using an EZ DNA Methylation-Gold kit
(Zymo). Bisulfite-converted DNA was processed and quantified using
Infinium HumanMethylation450 BeadChips (Illumina) and an iScan
system (Illumina). Methylation data analysis was conducted in R soft-
ware (R Core Team) using the chip analysis methylation pipeline
(ChAMP; Bioconductor) [18,19]. All data underwent basic quality
control and filtering before analysis as part of the CHAMP pipeline.
Data were normalized using the beta-mixture quantile correction
[20]. Differentially methylated probe (DMP) analysis was conducted
using ChAMP. Multiple comparisons were corrected using the Benja-
mini-Hochberg false discovery rate correction (0.001). Gene enrich-
ment analysis was conducted using DMP analysis outputs. DMPs
were filtered to include only those with a Db value difference
between groups of 0.5. The remaining DMPs were sorted by direc-
tion of methylation. Associated genes were compiled using the
RefSeq library. These gene lists were analyzed for significant terms in
the Allen Brain Atlas upregulated gene library using Enrichr [21,22].
Polymerase chain reaction and quantitative polymerase chain reaction
Protocol and primer sequences are described in Supplementary
Materials and Methods. For statistical analysis, independent t-tests
were conducted using SPSS 25.0 for each gene analyzed. Data are pre-
sented as mean § standard error of the mean of biological triplicates.
Electrophysiology
For electrophysiology, recordings and analyses were performed as
previously described. Human WGE iPSC STR cells were differentiated
using the protocol described above, but K/O and N2B27 media were
replaced with the previously described media [23].
Transplantation
Transplants were conducted as previously described [24]. Briefly,
500,000 cells were transplanted unilaterally into the quinolinic acid-
lesioned striatum, and rats received immunosuppression using cyclo-
sporin A (10mg/kg, Sandoz). After 7 weeks, rats were perfused trans-
cardially and the brains collected.
Results
Induced PSCs can be generated from hWGE tissues
To generate iPSCs, hWGE cells were harvested from four separate
human fetal samples (see supplementary Figure 1) and transfected
with the piggyBac transposon gene delivery vector system containing
the reprogramming genes OCT4, SOX2, KLF4, C-MYC and LIN28. This
resulted in the generation of multiple iPSC colonies from each hWGE
sample, and a single clone from each hWGE-derived iPSC population
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lines exhibited similar cell and colony morphology to hESC controls
and were composed of small rounded cells with a high nucleus to
cytoplasm ratio (Figure 1A). Pluripotent gene expression was demon-
strated across numerous passages in all four lines using RNA analysis
(Figure 1B) and immunocytochemistry staining (Figure 1C). Func-
tional pluripotency was demonstrated by derivation of all three germ
layers in vitro following spontaneous differentiation (Figure 1D) and
in vivo by teratoma formation in immune-deficient hosts (Figure 1E).
Collectively, these data demonstrate successful reprogramming of
cells harvested from primary hWGE to a pluripotent state.
Human WGE iPSCs and hESCs can differentiate toward an STR fate but
retain distinct methylation profiles
Using established principles of STR differentiation, we tested the
capacity of hWGE iPSCs to differentiate toward an STR phenotype
and included hESCs as a control. Successful fate specification was
confirmed using immunocytochemistry staining (Figure 2A; also see
supplementary Figure 2). In brief, dual SMAD inhibition led to the for-
mation of rosette structures typical of neuroectodermal progenitors,
identifiable by their flower-like morphology, and expression of ZO-1
at the luminal site and Nestin (NES) in the cytoplasm. Commitment to
a neuronal fate was confirmed by expression of b-III tubulin (TUBB3)
and MAP2. Patterning toward a ventral telencephalon progenitor fate
was initiated using SHH and DKK1 and confirmed by expression of
DLX1 and DLX2. Commitment to an MSN progenitor fate was induced
through exposure to Activin A. STR progenitor fate commitment was
confirmed by expression of ISL1, GSX2 and FOXP1. Following matura-
tion, MSNs were identified by positive co-expression of critical MSN
markers CTIP2 (BCL11B) and DARPP-32.
We then explored differences in CpG DNA methylation between
hWGE iPSCs and hESCs both at a pluripotent stage and following sub-
sequent STR differentiation. Differences in CpG methylation were
seen between hWGE iPSCs and hESCs, with more extensive hypome-
thylation in hWGE iPSCs (Figure 2B). Following STR differentiation,
both cell types exhibited demethylation changes in similar regions,
although the previously observed methylation differences between
PSC sources remained largely unchanged (Figure 2B). When compiled
into a multidimensional scaling plot, these differences separated
samples into four distinct groups: pluripotent hWGE iPSCs, pluripo-
tent hESCs, STR-differentiated hWGE iPSCs and STR-differentiated
hESCs (Figure 2C). Thus, following exposure to an STR differentiation
protocol, despite obvious sustained methylation differences, both
hWGE iPSCs and hESCs acquired similar demethylation changes. A
subset of these changes were revealed by gene enrichment analysis
to be significantly associated with terms related to the striatum and
its substructures (Figure 2D). Collectively, this demonstrates that
hWGE iPSCs respond similarly to key STR differentiation cues previ-
ously applied to hESCs and exhibit a similar capacity for STR differen-
tiation, yet there remain epigenetic differences between these cell
sources.
STR-differentiated hWGE iPSCs share characteristics with hWGE
We next sought to compare hWGE iPSCs following STR differenti-
ation (hWGE iPSC STR) with cells derived from hWGE (authentic STR
cells). RNA analysis (Figure 3A) revealed similar levels of pan-neuro-
nal markerMAP2 (t9 = 1.173, P = 0.105), suggesting similar neuronal
composition. Between the two cell types there was no significant dif-
ference in FOXP1 expression (t9 = 0.145, P = 0.398). However, hWGE
iPSC STR cells expressed greater levels of FOXP2 (t9 = 3.567,
P = 0.006) and DARPP-32 (t9 = 2.473, P = 0.035), whereas hWGE
expressed greater levels of GAD65/67 (t9 = 4.173, P = 0.002). GSX2,
DLX2 and NKX2-1 are known to be upregulated in the ventral telen-
cephalon, but their expression is reduced in mature MSNs. All threewere expressed at significantly lower levels in the hWGE iPSC STR
cells (GSX2 t9 = 7.662, P < 0.001; DLX2 t9 = 9.307, P < 0.001; NKX2-1
t9 = 3.743, P = 0.005), implying maturation of these cells.
We also explored potential functional differences between these
cell types using patch clamp electrophysiological analysis at early
(2130 days) and late (4245 days) time points (Figure 3B; also see
supplementary Table 3). A higher percentage of hWGE iPSC STR cells
displayed induced action potentials (APs) compared with hWGE
(hWGE iPSC STR, early 89%, late 100%; hWGE, early 70%, late 40%),
and the amplitude of induced APs was higher in hWGE iPSC STR cells
than in hWGE. A single spontaneous AP was seen in hWGE iPSC STR
cells, but none was seen in hWGE. The output values for the resting
membrane potential evaluations (typically in the range of 50 mV to
70 mV in more mature neurons) indicated low levels of maturity in
all neurons (hWGE iPSC STR, early 35.4 § 3.6 mV, late 28.6 § 2.4
mV; hWGE, early 33.9 § 5.3 mV, late 37.3 § 4.9 mV; all values
mean § standard error of the mean). Thus, the electrophysiological
analysis suggested overall neuronal immaturity, although this was
less marked in the hWGE iPSC STR cells.
Finally, either hWGE iPSC STR cells or hWGE was transplanted
into the lesioned rat striatum, and grafts were collected 7 weeks
post-transplantation for immunohistochemical analysis. Graft sur-
vival and volume were analyzed using human nuclear antigen, a
human-specific marker (Figure 3C). No significant differences in vol-
ume were found in grafts derived from either hWGE iPSC STR cells or
hWGE (P = t15 = 2.95, P = 0.086) (Figure 3D). However, a significantly
higher proportion of the grafted hWGE iPSC STR cells were positive
for the MSN marker DARPP-32 (human-specific) (t15 = 33.75, P <
0.001) (Figure 3D). Subsequently, hWGE iPSC STR-derived grafts
appeared to have yielded a greater number of mature MSNs per unit
volume than hWGE-derived grafts.
Discussion
There is a need to find alternative donor cell sources (most likely
PSCs) for future application of CRT for HD. It is known that iPSCs
retain some epigenetic features of their tissue of origin and that this
can enhance differentiation of fates associated with the tissue of ori-
gin [8,9]. Thus, iPSCs derived from hWGE could harness their residual
epigenome to enhance STR fate differentiation. Here we take the
essential first steps to explore this potential donor source.
We have demonstrated the first successful generation of iPSC lines
from four separate hWGE tissues and validated their pluripotency.
Using developmental principles previously applied to hESCs for STR
differentiation [2527], we found that these hWGE iPSCs differenti-
ate into neurons expressing a range of MSN markers, including
FOXP1, CTIP2 and DARPP-32, similar to what is achievable with hESCs.
We also examined the methylome of hWGE iPSCs and hESCs exposed
to the STR differentiation protocol and demonstrated significant
demethylation at CpG sites associated with STR genes in both, consis-
tent with the current understanding of the developmental role of
methylation [28]. However, although hWGE iPSCs and hESCs
appeared to have differentiated into equivalent STR phenotypes in
terms of selected STR markers and the demethylation of STR genes,
obvious methylome differences persisted. As mentioned, it has been
established that iPSCs can retain an epigenetic memory of their tissue
of origin, which enhances their capacity to differentiate toward cell
fates associated with that original tissue. Human WGE iPSCs may
benefit from an epigenetic memory retained from their STR origin,
and this epigenetic background may allow such cells to be more suit-
able for STR differentiations than hESCs. However, elucidating the
functional consequences of the retained methylome differences
observed here, or even how the observed demethylation of STR genes
compares with that of normal development, will need to be accom-
plished in future work by directly comparing hWGE iPSC lines with
human iPSCs derived from non-STR tissues, hESCs and hWGE tissues.
Figure 1. Induced PSCs can be generated from hWGE tissues. (A) Images of hESC and human iPSC colonies. (B) RT-PCR of OCT4, SOX2, NANOG, LIN28 and C-MYC expression in undif-
ferentiated hWGE iPSCs. (C) ICC for OCT4 (green), SOX2 (green) and TRA-1-60 (red) in undifferentiated hWGE iPSCs. (D) ICC for endoderm (vimentin, left, red; AFP, right, red), meso-
derm (a-SMA, left, red; desmin, right, green) and ectoderm (nestin, left, green; b-III tubulin, right, green) with Hoechst (blue) in in vitro spontaneously differentiated hWGE iPSCs.
(E) Hematoxylin and eosin staining in teratomas from immune-deficient mice following subcutaneous injection of hWGE iPSCs. Arrows indicate adipose and gland-like tissues
(endoderm), chondroblasts and smooth muscle fibers (mesoderm) and neural rosettes (ectoderm). RT-PCR, reverse transcription-polymerase chain reaction; ICC, immunocyto-
chemistry staining; AFP, alpha fetoprotein; SMA, smooth muscle actin.
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Figure 2. Human WGE iPSCs can differentiate toward an STR fate but retain distinct methylation profiles. (A) Human WGE iPSCs undergoing STR differentiation: neuroectodermal
progenitors expressing ZO-1 (red) and Nestin (green) (day 12 to day 14); ventral telencephalon progenitors expressing DLX1 (red) and DLX2 (green) (day 14 to day 18); STR progeni-
tors expressing b-III tubulin (red) and ISL1 (green) (day 18 to day 25); MSNs expressing CTIP2 (red) and DARPP-32 (green) (day 35 to day 45); and a phase contrast image showing
mature neuronal morphology (see also supplementary Figure 2). (B) Heat map and (C) MDS plot of the 1000 most variably methylated probes between undifferentiated PSCs and
differentiated STR cells. (D) Results of gene enrichment analysis of differentially methylated genes between PSC (n = 3) and STR (n = 3) samples, showing the top four most signifi-
cant associated terms in the Allen Brain Atlas upregulated gene library, adjusted Pvalues and associated genes. MDS, multidimensional scaling.
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Figure 3. STR-differentiated hWGE iPSCs share characteristics with hWGE. (A) QPCR analysis showing relative gene expression in hWGE iPSC STR cells (n = 5) relative to hWGE
(n = 6). (B) Electrophysiological assessment of hWGE iPSC STR cells and hWGE (see also supplementary Table 3). (C) Images of hWGE iPSC STR cells and hWGE grafts: immunohisto-
chemical staining for HuNu (brown) and immunofluorescent staining for HuNu (red) and human-specific DARPP-32 (huDARPP-32, green). (D) Graft volume and counts of DARPP-32
cells per graft. *P< 0.05, **P< 0.01, ***P< 0.001. HuNu, human nuclear antigen; QPCR, quantitative polymerase chain reaction.
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of MSNs: hWGE. Gene expression analysis of in vitro cultures sug-
gested that hWGE iPSC STR cells were overall more mature than their
hWGE counterparts. Specifically, despite similar levels of MAP2 and
FOXP1 expression, we found significantly higher DARPP-32 expres-
sion in the hWGE iPSC STR cells. Conversely, significantly higher
expression of earlier ventral telencephalic markers GSX2, DLX2 and
NKX2-1 were observed in hWGE samples. Electrophysiological analy-
sis corroborated these findings. Human WGE iPSC STR cells exhibited
a greater number of APs and at higher amplitudes than the hWGE-
derived cells, although in all cases the amplitudes were lower than
anticipated in fully mature neurons.
Following intra-STR transplantation into an HD model, we
observed significantly greater numbers of DARPP-32-expressing cells
in hWGE iPSC STR grafts compared with hWGE grafts, despite graft
volumes being similar. We cannot comment on the functionality of
these grafts, although we can confirm the readiness of hWGE iPSCs to
differentiate into MSNs in vivo. There are a number of potential
explanations as to why these grafts appear to be enriched for DARPP-
32-positive cells compared with hWGE. For example, STR differentia-
tion is designed to produce MSN progenitors, rather than a full com-
plement of hWGE cells (e.g., STR interneurons), which is consistent
with the higher expression of GAD65/67 (expressed by both MSNs
and STR interneurons) observed in hWGE. Alternatively, these differ-
ences could result from the variances in maturity suggested by our in
vitro data, and further in vivo graft maturation could perhaps alleviate
these differences.
In summary, although hWGE iPSCs appear to possess an STR dif-
ferentiation capacity similar to that of hESCs, their methylation pro-
files remain distinct. It is possible that these differences represent an
epigenetic memory of tissue of origin, which could enable hWGE
iPSCs to produce MSNs that are more similar to their original tissue:
hWGE. We have established that hWGE iPSCs produce MSNs that
share fundamental characteristics with hWGE-derived MSNs, thus
confirming their potential as a useful alternative cell source for CRT
for HD and offering evidence that such cell lines may be capable of
overcoming the limitations of fetal tissues.Declaration of Competing Interest
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